Hasten Biopharmaceutical buys asset rights for 14 branded products from Celltrion
In a significant move, CBC Group, Asia's largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its portfolio company, Hasten Biopharmaceutical, has successfully acquired ... Read More
Harbour BioMed resubmits BLA for batoclimab to China’s NMPA for generalized myasthenia gravis
Harbour BioMed (HKEX: 02142), a prominent global biopharmaceutical company, has announced the resubmission of the Biologics License Application (BLA) for batoclimab (HBM9161) to the National ... Read More
Vanda Pharmaceuticals rejects Future Pak’s acquisition offer
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has officially declined the latest acquisition proposal from Future Pak, LLC (FP), citing substantial undervaluation and significant risk. The offer, ... Read More
Seaport Therapeutics rakes in $100m for neuropsychiatric medicine advancement
Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical company, has successfully closed an oversubscribed Series A financing round, securing $100 million. This significant milestone was led by ... Read More
Ascentage Pharma showcases novel drug candidates at AACR 2024
Ascentage Pharma (6855.HK), a prominent global biopharmaceutical firm, recently unveiled the latest preclinical study results for its innovative drug candidates at the American Association of ... Read More
InnoCare Pharma, ArriVent BioPharma initiate Phase 1b clinical trial in NSCLC
InnoCare Pharma, listed on both the Hong Kong Stock Exchange (HKEX: 09969) and the Shanghai Stock Exchange (SSE: 688428), along with ArriVent BioPharma, Inc. (Nasdaq: ... Read More
FDA approves Akebia Therapeutics’ Vafseo for anemia in dialysis patients
In a significant development for the treatment of anemia related to chronic kidney disease (CKD) in dialysis patients, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a pioneering ... Read More
AbbVie to acquire Landos Biopharma to bolster autoimmune disease treatments
AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, Inc. (NASDAQ: LABP) have announced a landmark agreement, marking a strategic move in the biopharmaceutical sector focused on ... Read More
LENZ Therapeutics announces merger with Graphite Bio to revolutionize presbyopia treatment
In a significant move for the biopharmaceutical industry, LENZ Therapeutics, Inc. (Nasdaq: LENZ), a trailblazer in developing innovative treatments for presbyopia, announced the successful completion ... Read More